Tag: Mithra
Mithra CDMO announces collaboration with MedinCell for the development of injectables against malaria and transplant rejection – 04/26/2022 at 07:30
Liège, Belgium, April 26, 2022 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, announces today that it has signed a partnership agreement with MedinCell…
Mithra publishes the invitation to its ordinary and extraordinary general meeting of security holders – 04/19/2022 at 07:45
Liège, Belgium, April 19, 2022 – 7:45 am CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces its invitation to the ordinary and extraordinary general…
Mithra Pharmaceuticals SA: Extension of the duration of the capital commitment agreement with LDA capital for a period of two years and increase of EUR 25 million in the total amount of the commitment
Liège, Belgium, April 18, 2022 -07:30 CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (“Mithra” or the “Company”), a company dedicated to women’s health, today announces the extension of the…
Mithra publishes its 2021 annual report – 04/15/2022 at 07:30
Liège, Belgium, April 15, 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces the publication of its 2021 annual report. The annual…
Mithra and Searchlight Pharmaceuticals announce the commercial launch of Haloette® in Canada – 02/16/2022 at 07:30
LIÈGE (Belgium – 7:30 AM CET) and MONTREAL (Canada – 7:00 AM EST), February 16, 2022 – Mithra and Searchlight Pharmaceuticals are pleased to announce the commercial launch of the…
Mithra secures €100 million equity financing – 02/07/2022 at 07:30
Liège, Belgium, February 7, 2022 – 7:30 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces that it has…
Mithra: stated objective
Through Hector Chaunu Published on 01/14/2022 at 11:57 Photo credit © Reuters The society Mithras presents the first results of phase III evaluating Donesta in postmenopausal women with vasomotor symptoms…